Enspryng (satralizumab-mwge) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Image 1-Enspryng™ (satralizumab-mwge)
Enspryng™ (satralizumab-mwge) is a prescription medicine indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD). Credit: Business Wire.